Cape Town carries one of the world's heaviest tuberculosis burdens, and its drug-resistant cases fall hardest on the Cape Flats townships. The same city offers two tiers of care: private clinics with rapid testing and reliable drugs, and public clinics where delays and stockouts are routine. This piece examines how that split shapes survival, and what clinicians and policymakers can do about it.

Two Cities Under One Mountain

Cape Town's tuberculosis epidemic is among the most intense globally, with incidence rates that rival those of many low-income countries. Yet the city's wealth gradient produces sharply divergent experiences of the same disease. In the leafy southern suburbs, private patients with drug-resistant TB can expect prompt diagnosis and uninterrupted treatment. In the Cape Flats townships, the same diagnosis often means months of delay, drug shortages, and difficult choices between health and livelihood.

This pattern is not unique to TB. A related piece on this site describes how malaria in infants is treated late at both ends of the income scale, though for different reasons. In Cape Town, the split is starker because the disease is airborne and untreated cases fuel community transmission. The result is a vicious cycle: poor care in townships drives resistance, which then spreads back to wealthier areas.

Public clinics in the townships report waiting times of several hours and frequent stockouts of second-line drugs. Private clinics, by contrast, often have molecular testing on site and a steady supply of newer medications. This disparity persists despite national guidelines that promise equitable access.

The geography itself tells the story. The Cape Flats is a broad, low-lying expanse of formal and informal housing where several hundred thousand people live, many in overcrowded conditions that favour airborne spread. Household crowding, shared sanitation, and poor ventilation are well-recognised drivers of transmission, and they cluster precisely where incomes are lowest. A patient in Khayelitsha may share a dwelling with several generations, making isolation after diagnosis close to impossible. In the southern suburbs, the same diagnosis means a spare room and a closed door.

The Cost of a Missed Diagnosis

Rapid molecular testing, such as the GeneXpert system, can identify drug-resistant TB within hours. But many township clinics lack the equipment or the staff to run it consistently. As a result, patients may be started on first-line treatment that fails, allowing resistance to amplify. A missed diagnosis not only harms the individual but also extends the period of infectiousness.

Multidrug-resistant TB (MDR-TB) is defined by resistance to at least isoniazid and rifampicin, the two most powerful first-line drugs. Extensively drug-resistant TB (XDR-TB) adds resistance to second-line agents, narrowing options and raising mortality. In Cape Town, XDR-TB cases are concentrated in areas with high HIV prevalence and poor infection control.

Delays in diagnosis push patients toward second-line regimens that are longer, more toxic, and more expensive. For patients in the townships, the cost of a missed diagnosis is measured in months of illness and lost income. Community health workers sometimes bridge the gap by transporting sputum samples, but this is an ad hoc solution.

There is a laboratory dimension that rarely makes it into policy discussions. Sputum samples have to be collected, stored, and transported under conditions that preserve the organism, and a sample that sits too long or gets too warm can produce a false negative. In practice this means a patient may be told they are smear-negative and sent home, only to return weeks later sicker and more infectious. The fix is unglamorous: reliable cold-chain logistics, functioning courier routes, and enough trained technicians to process samples within a day or two of collection. None of these are research breakthroughs, which may be why they attract less attention than new drug candidates.

Daily Life on Injectable and Oral Regimens

Treatment for drug-resistant TB can stretch from nine to twenty months, depending on the regimen and response. Older drugs cause hearing loss, nausea, and psychosis. Newer drugs like bedaquiline and linezolid are better tolerated but not always available in the public sector. Patients must balance clinic visits with work and family obligations, often choosing between wages and health.

In the townships, transport costs and distance to clinics add another layer of burden. A related article on community health workers catching newborn sepsis in Malawi shows how lay health workers can extend reach where labs are scarce. In Cape Town, community health workers help with directly observed therapy and provide psychosocial support, but their numbers are insufficient.

Adherence is further complicated by food insecurity. Many patients on TB treatment need adequate nutrition to recover, yet poverty makes this difficult. Stigma also keeps some patients from disclosing their status, leading to delayed care and silent transmission.

The injectable era left a particular mark. Older aminoglycoside regimens required months of painful intramuscular injections, and hearing loss was a common and permanent consequence. Clinicians describe patients who finished treatment cured of TB but deaf, unable to work in noisy environments or to hear their children. The shift toward all-oral regimens is one of the most consequential improvements in decades, but it only helps patients who can actually get the drugs. Where supply is erratic, clinics fall back on whatever is in the cupboard, and that may be the older, harsher option.

There is also the question of what treatment does to a household's finances. A course of drug-resistant TB can consume a substantial share of a poor family's monthly income once transport, food, and lost wages are counted. Studies of patient costs in high-burden settings consistently find that the indirect costs, travel and time away from work, often exceed the direct medical costs, which may themselves be nominally free. Free drugs are not the same as free care.

What the Wealth Gradient Does to Adherence

Private patients often access bedaquiline and linezolid sooner, thanks to medical aid or out-of-pocket payments. In the public sector, stockouts of these drugs disrupt continuity, forcing clinicians to substitute older, more toxic regimens. This inconsistency undermines trust and increases the risk of treatment failure.

Food insecurity is a major barrier in poorer suburbs. Without reliable nutrition, patients struggle to complete treatment, and relapse becomes more likely. Stigma adds another layer: in tight-knit communities, being seen at a TB clinic can lead to social isolation or job loss.

The wealth gradient also affects adherence support. Private clinics may offer SMS reminders and flexible appointment times, while public clinics are often overcrowded and understaffed. A piece on hypertension diagnoses arriving after the stroke in Brazil's Northeast echoes this pattern of late presentation among the poor.

Trust is the variable that gets least attention in adherence research. A patient who has been told twice that their drugs are coming next week, and twice found the pharmacy shelf empty, learns something about the health system. When the same patient is then counselled about the importance of not missing doses, the message lands badly. Clinicians working in these settings describe spending as much time managing expectations and repairing credibility as managing the disease itself. That labour is real, it is exhausting, and it is invisible in most reporting systems.

Lessons From the City's Split Geography

Decentralised care models in Khayelitsha have shown promise. By bringing treatment closer to home and involving nurses in initiation, these programmes reduce delays and improve adherence. Mobile screening units have also reached underserved neighbourhoods, finding cases that would otherwise go undetected.

Nurse-led initiation cuts the time from diagnosis to treatment, which is critical for reducing transmission. However, data sharing between public and private sectors lags, hindering a coordinated response. Without integrated data, the city cannot track resistance patterns or allocate resources effectively.

The split geography of Cape Town offers a natural experiment. Where decentralisation has been implemented, outcomes improve. Where it has not, the gap widens. The challenge is scaling these models across the city.

Scaling is harder than piloting, for reasons that are structural rather than scientific. A decentralised site needs a steady nurse complement, a reliable drug supply, a working GeneXpert module, and a referral pathway for complicated cases. Remove any one of those and the model degrades into a queue with a different postcode. Funders tend to support the launch and move on before the maintenance costs arrive, which is one reason pilot results so often fail to replicate at city scale.

Actions for Clinicians and Policymakers

Clinicians and policymakers can take concrete steps to close the gap. First, expand rapid molecular testing to all primary clinics, ensuring that every patient with suspected TB receives a same-day diagnosis. Second, fund uninterrupted supplies of second-line drugs, with buffer stocks to prevent stockouts. Third, integrate TB care with food and transport support, recognising that adherence is impossible on an empty stomach or without a bus fare. Fourth, train community health workers in resistance screening and adherence support, and deploy them in sufficient numbers. Fifth, publish disaggregated outcomes by township and suburb, so that disparities are visible and accountable.

These actions are not costly relative to the burden of untreated disease. They require political will and a commitment to equity. Without them, Cape Town will continue to have two TB epidemics, one manageable and one deadly.

This article is for informational purposes only and does not constitute personalised medical advice. Readers should consult qualified healthcare professionals for guidance on diagnosis and treatment.